A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diuretic) 12.5-25 mg added if necessary.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
30 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Arterial hypertension without previous regular treatment
Urinary albumin excretion rate above 30 mg / 24h
30-65 years old
Reno-vascular arterial hypertension
Therapy resistant edema
Chronic heart failure, angina pectoris
Other protocol-defined exclusion criteria may apply